Tumor formation rate was slightly lower in antibody treated group (6/15) as compared with control group (5/10), and tumor growth was significantly inhibited by antibody treatment, which suggested that antibody against PRM1 does not only inhibit CRC growth, but also have a certain impact on tumorigenesis (Fig. S9). This evidence concerns the gene PRM1 and colorectal carcinoma.